Deutsche Bank upgrades Astrazeneca to 'hold'

The broker noted that the stock has fallen around 3% in absolute terms since its downgrade last October and lagged the sector by roughly 10% on an FX—adjusted basis.It said part of the weakness reflected factors it had anticipated - including second—half event risk and patent—cliff concerns - while…